Evaluation of a MOPP type regimen in histiocytosis X

A southwest oncology group study

D. M. Komp, M. Silva-Sosa, T. Miale, C. Sexauer, Jay Herson

Research output: Contribution to journalArticle

Abstract

The overall 38% response rate in histiocytosis X for cyclophosphamide, vincristine (Oncovin), prednisone, and procarbazine was not superior to responses that can be achieved with the component single agents. This is in contrast to the higher response rates that can be achieved by the combination of these agents in Hodgkin's disease. This is the second study of combination chemotherapy with individually effective agents that has failed to improve the response rates in histiocytosis patients with poor prognostic indicators.

Original languageEnglish (US)
Pages (from-to)855-859
Number of pages5
JournalCancer Treatment Reports
Volume61
Issue number5
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Langerhans Cell Histiocytosis
Vincristine
Histiocytosis
Procarbazine
Prednisone
Combination Drug Therapy
Hodgkin Disease
Cyclophosphamide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of a MOPP type regimen in histiocytosis X : A southwest oncology group study. / Komp, D. M.; Silva-Sosa, M.; Miale, T.; Sexauer, C.; Herson, Jay.

In: Cancer Treatment Reports, Vol. 61, No. 5, 01.12.1977, p. 855-859.

Research output: Contribution to journalArticle

Komp, DM, Silva-Sosa, M, Miale, T, Sexauer, C & Herson, J 1977, 'Evaluation of a MOPP type regimen in histiocytosis X: A southwest oncology group study', Cancer Treatment Reports, vol. 61, no. 5, pp. 855-859.
Komp, D. M. ; Silva-Sosa, M. ; Miale, T. ; Sexauer, C. ; Herson, Jay. / Evaluation of a MOPP type regimen in histiocytosis X : A southwest oncology group study. In: Cancer Treatment Reports. 1977 ; Vol. 61, No. 5. pp. 855-859.
@article{9f14e76206f3458c948b8814d891df81,
title = "Evaluation of a MOPP type regimen in histiocytosis X: A southwest oncology group study",
abstract = "The overall 38{\%} response rate in histiocytosis X for cyclophosphamide, vincristine (Oncovin), prednisone, and procarbazine was not superior to responses that can be achieved with the component single agents. This is in contrast to the higher response rates that can be achieved by the combination of these agents in Hodgkin's disease. This is the second study of combination chemotherapy with individually effective agents that has failed to improve the response rates in histiocytosis patients with poor prognostic indicators.",
author = "Komp, {D. M.} and M. Silva-Sosa and T. Miale and C. Sexauer and Jay Herson",
year = "1977",
month = "12",
day = "1",
language = "English (US)",
volume = "61",
pages = "855--859",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Evaluation of a MOPP type regimen in histiocytosis X

T2 - A southwest oncology group study

AU - Komp, D. M.

AU - Silva-Sosa, M.

AU - Miale, T.

AU - Sexauer, C.

AU - Herson, Jay

PY - 1977/12/1

Y1 - 1977/12/1

N2 - The overall 38% response rate in histiocytosis X for cyclophosphamide, vincristine (Oncovin), prednisone, and procarbazine was not superior to responses that can be achieved with the component single agents. This is in contrast to the higher response rates that can be achieved by the combination of these agents in Hodgkin's disease. This is the second study of combination chemotherapy with individually effective agents that has failed to improve the response rates in histiocytosis patients with poor prognostic indicators.

AB - The overall 38% response rate in histiocytosis X for cyclophosphamide, vincristine (Oncovin), prednisone, and procarbazine was not superior to responses that can be achieved with the component single agents. This is in contrast to the higher response rates that can be achieved by the combination of these agents in Hodgkin's disease. This is the second study of combination chemotherapy with individually effective agents that has failed to improve the response rates in histiocytosis patients with poor prognostic indicators.

UR - http://www.scopus.com/inward/record.url?scp=0017684465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017684465&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 855

EP - 859

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -